Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedIPD sharing language was added, outlining access for researchers, conditions for data sharing, and how to request IPD via Vivli. It also references related privacy protections and public availability timelines.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a minor patch to the page's metadata.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, indicating a small platform update that does not alter the study details or displayed content.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded external registry identifiers JapicCTI-194983, NMRR-19-1491-48537, jRCT2080224898, and CTR20192589 to the study record. Removed older milestone dates (2026-02-27, 2026-02-26, 2026-02, 2026-05-01) and added new dates (2026-07-13, 2026-06-17, 2026-06, 2026-12-31).SummaryDifference0.2%

- Check52 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a new build of the page content. This update reflects an updated release of study documents and related UI elements.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a small platform update. No study content or data appears to be affected.SummaryDifference0.0%

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.